GSK plc
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), GSK plc reported 15 stock positions worth $799.0 million. Its top holding was Wave Life Sciences (WVE) at 38.8% of the portfolio, followed by Crispr Therapeutics (CRSP, 21.1%) and Biontech SE-ADR (BNTX, 10.6%).
- Most Recent 13F
- Q2 2026
- Location
- London, X0
- CIK
- 0001131399
- Portfolio Value
- $799.0M (Q4 2025)
- SEC Filing
- 0001999371-26-003198 ↗ filed Feb 12, 2026
Holdings Value
Holdings 15 stocks · $799.0M
| WVE Wave Life Sciences Ltd. | 38.82% | 18,245,691 | $310.2M | — |
| CRSP Crispr Therapeutics AG | 21.14% | 3,220,627 | $168.9M | — |
| BNTX Biontech SE-ADR | 10.60% | 889,824 | $84.7M | — |
| VIR Vir Biotechnology Inc. | 6.45% | 8,550,954 | $51.6M | — |
| LYEL Lyell Immunopharma Inc. | 5.83% | 1,512,659 | $46.6M | — |
| IDYA Ideaya Biosciences Inc. | 5.77% | 1,333,333 | $46.1M | — |
| CYTK Cytokinetics Inc. | 2.71% | 340,434 | $21.6M | — |
| SPRO Spero Therapeutics Inc. | 2.68% | 9,190,606 | $21.4M | — |
| FULC Fulcrum Therapeutics Inc. | 2.53% | 1,785,714 | $20.2M | — |
| BCYC Bicycle Therapeutics PLC-ADR | 1.36% | 1,529,561 | $10.8M | — |
| CVRX CVRX Inc. | 0.90% | 1,007,583 | $7.2M | — |
| NKTX Nkarta Inc. | 0.73% | 3,150,732 | $5.8M | — |
| RGNX Regenxbio Inc. | 0.49% | 271,456 | $3.9M | — |
| SENS Senseonics Holdings Inc. | 0.01% | 10,856 | $60K | — |
| HBIO Harvard Bioscience Inc. | 0.00% | 11,151 | $7K | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.